The LEPIS-HuR-TMOD4 axis regulates hepatic cholesterol homeostasis and accelerates atherosclerosis
Ping LYuiD, Hangyu Pan, Kexin Hu, Yazhi Xue, Qinxian Li, Rongzhan LiniD, Shaoyi ZhengiD, Zhigang GuoiD, Kai GuoiD
Abstract
Long noncoding RNAs (lncRNAs) play an important role in the entire progression of atherosclerosis. In this study, we identified an uncharacterized lncRNA, Liver Expressions by PSRC1 Induce Specifically (LEPIS). The expression of LEPIS and its potential target tropomodulin 4 (TMOD4) in the liver of ApoE-/- mice fed a high-fat diet was increased. An ApoE-/- mouse model with the overexpression of LEPIS or TMOD4 in liver was established, and we found that both LEPIS and TMOD4 increased the burden of atherosclerosis and reduced hepatic cholesterol levels. Further study revealed that LEPIS and TMOD4 affect the expression of genes related to hepatic cholesterol homeostasis, including proprotein convertase subtilisin/kexin type9 (PCSK9) and low-density lipoprotein receptor (LDLR), which are closely related to hypercholesterolemia. Mechanistically, human antigen R (HuR), an RNA-binding protein, was shown to be critical for the regulation of TMOD4 by LEPIS. Further, we found that overexpression of LEPIS promoted the shuttling of HuR from the nucleus to the cytoplasm, enhanced the stability of TMOD4 mRNA, and in turn promoted the expression of TMOD4. In addition, TMOD4 was found to affect intracellular cholesterol levels through PCSK9. These results suggest that the LEPIS-HuR-TMOD4 axis is a potential intervention target for hepatic cholesterol homeostasis and atherosclerosis. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=183 SRC="FIGDIR/small/490400v1_ufig1.gif" ALT="Figure 1"> View larger version (59K): org.highwire.dtl.DTLVardef@c4af60org.highwire.dtl.DTLVardef@d5e7d1org.highwire.dtl.DTLVardef@1667d08org.highwire.dtl.DTLVardef@19abddd_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 4
- FWCI
- 1.68
- Field percentile
- top 17%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting Liver Epsins Ameliorates Dyslipidemia in Atherosclerosis through Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9-Mediated Low-density Lipoprotein Receptor Degradation
Bo Zhu, Krishan Gupta, … Hong Chen·bioRxiv·Aug 26, 2024
- Beneficial Effects of Moderate Hepatic Activin A Expression on Metabolic pathways, Inflammation, and Atherosclerosis
H. Liu, M. H. Hastings, … A. Rosenzweig·bioRxiv·Jul 5, 2022
- Hepatic inactivation of murine Surf4 results in marked reduction in plasma cholesterol
V. T. Tang, J. McCormick, … D. Ginsburg·bioRxiv·Aug 1, 2022
- Lzp Ablation Ameliorates Dyslipidemia and Suppresses Atherosclerosis by Reducing Circulating Apolipoprotein B-Containing Lipoproteins
Kunyan He, Xin Ku, … Ze‐Guang Han·bioRxiv·Sep 24, 2025
- TOMM40 regulates hepatocellular and plasma lipid metabolism via an LXR-dependent pathway
Neil Victor Yang, Justin Y. Chao, … Ronald M. Krauss·Molecular MetabolismPeer-reviewed·Nov 1, 2024
- Loss of embryonically-derived Kupffer cells during hypercholesterolemia accelerates atherosclerosis development
R. Fima, S. Dussaud, … T. Huby·bioRxiv·Sep 26, 2023